High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

by Atsushi Osoegawa, MD, PhD, Masafumi Yamaguchi, MD, PhD, Tomomi Nakamura, MD, PhD, Ryotaro Morinaga, MD, Kentaro Tanaka, MD, PhD, Kosuke Kashiwabara, MD, PhD, Takashi Miura, MD, PhD, Takayuki Suetsugu, MD, PhD, Taishi Harada, MD, PhD, Tatsuma Asoh, MD, PhD, Kenichi Taguchi, MD, PhD, Kazuki Nabeshima, MD, PhD, Junji Kishimoto, MA, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kenji Sugio, MD, PhD
Published 2021-07-01

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

by Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Published 2021-06-01